Aclarion (ACON) Stock Price, News & Analysis

Company Overview

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Key Stats

• Today's Range: $0.17 to $0.18
• 50-Day Range: $0.16 to $0.23
• 52-Week Range: $0.16 to $7.40
• Volume: 132,147 shs
• Average Volume: 1.44 million shs
• Market Capitalization: $1.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Buy

Aclarion Stock Analysis - MarketRank™

Aclarion scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aclarion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aclarion has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aclarion are expected to grow in the coming year, from ($0.86) to ($0.73) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.50% of the float of Aclarion has been sold short.

Short Interest Ratio / Days to Cover

Aclarion has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclarion has recently increased by 42.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aclarion does not currently pay a dividend.

Dividend Growth

Aclarion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.50% of the float of Aclarion has been sold short.

Short Interest Ratio / Days to Cover

Aclarion has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclarion has recently increased by 42.27%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Aclarion has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Aclarion this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for ACON on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aclarion insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of Aclarion is held by insiders.

Percentage Held by Institutions

Only 7.52% of the stock of Aclarion is held by institutions.

ACON Stock Analysis - Frequently Asked Questions

How have ACON shares performed this year?

Aclarion's stock was trading at $3.20 at the beginning of 2024. Since then, ACON stock has decreased by 94.5% and is now trading at $0.1764.
View the best growth stocks for 2024 here.

How were Aclarion's earnings last quarter?

Aclarion, Inc. (NASDAQ:ACON) issued its earnings results on Wednesday, August, 14th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. The business earned $0.01 million during the quarter. Aclarion had a negative trailing twelve-month return on equity of 422.87% and a negative net margin of 12,845.05%.

When did Aclarion's stock split?

Aclarion shares reverse split before market open on Thursday, January 4th 2024. The 1-16 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Aclarion IPO?

Aclarion (ACON) raised $12 million in an IPO on Friday, April 22nd 2022. The company issued 2,165,000 shares at a price of $4.50-$6.50 per share.

How do I buy shares of Aclarion?

Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aclarion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclarion investors own include Broadcom (AVGO), Meta Platforms (META), Norwegian Cruise Line (NCLH), AudioEye (AEYE), Advanced Micro Devices (AMD), ASML (ASML) and AvidXchange (AVDX).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:ACON
• CUSIP: N/A
• CIK: 1635077
• Web: www.aclarion.com
• Phone: 833-275-2266
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.50
• High Stock Price Target: $1.50
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +750.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,910,000.00
• Net Margins: -12,845.05%
• Pretax Margin: -12,845.05%
• Return on Equity: -422.87%
• Return on Assets: -201.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.80
• Quick Ratio: 2.80

Sales & Book Value

• Annual Sales: $49,289.00
• Price / Sales: 37.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.38) per share
• Price / Book: -0.46

Miscellaneous

• Outstanding Shares: 10,431,000
• Free Float: 10,254,000
• Market Cap: $1.84 million
• Optionable: Not Optionable
• Beta: 0.39